Damora Therapeutics (DMRA) Change in Cash (2019 - 2026)

Damora Therapeutics has reported Change in Cash for 8 years, with the latest figure at $275.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 11388.36% year-over-year to $275.3 million; the trailing twelve-month figure through Mar 2026 stood at $520.5 million (up 5803.55% YoY), and the FY2025 full-year result was $242.7 million, up 3581.2% from the prior year.
• Change in Cash for Q1 2026 stood at $275.3 million, up from $250.0 million in the prior quarter.
• The five-year high for Change in Cash was $275.3 million in Q1 2026, with the low at -$17.0 million in Q1 2022.
• Historically, Change in Cash has averaged $27.6 million across 5 years, with a median of -$2.1 million in 2023.
• Annual changes were most pronounced in 2024 — Change in Cash slumped 182650.0% — and 2026, when it soared 11388.36%.
• Damora Therapeutics' Change in Cash stood at $2.9 million in 2022, then slumped by 164.27% to -$1.9 million in 2023, then sank by 160.61% to -$4.9 million in 2024, then soared by 5165.56% to $250.0 million in 2025, then advanced by 10.11% to $275.3 million in 2026.
• The last three Change in Cash figures came in at $275.3 million (Q1 2026), $250.0 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.